Givosiran sodium - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic drug sources for givosiran sodium and what is the scope of patent protection?
Givosiran sodium
is the generic ingredient in one branded drug marketed by Alnylam Pharms Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Givosiran sodium has four hundred and thirteen patent family members in forty-two countries.
One supplier is listed for this compound.
Summary for givosiran sodium
| International Patents: | 413 |
| US Patents: | 14 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in givosiran sodium? | givosiran sodium excipients list |
| DailyMed Link: | givosiran sodium at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for givosiran sodium
US Patents and Regulatory Information for givosiran sodium
Expired US Patents for givosiran sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alnylam Pharms Inc | GIVLAARI | givosiran sodium | SOLUTION;SUBCUTANEOUS | 212194-001 | Nov 20, 2019 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for givosiran sodium
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2016033136 | ｉＲＮＡ複合体 (iRNA COMPLEX) | See Plans and Pricing |
| Canada | 2568735 | COMPOSITION A DOUBLE BRIN COMPRENANT DES BRINS DIFFERENTIELLEMENT MODIFIES UTILISES DANS LA MODULATION GENETIQUE (DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION) | See Plans and Pricing |
| Guatemala | 201600066 | COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DEL GEN ALAS1 | See Plans and Pricing |
| Austria | 460481 | See Plans and Pricing | |
| Germany | 10100586 | Verfahren zur Hemmung der Expression eines Ziegens (Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases) | See Plans and Pricing |
| Spain | 2321409 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for givosiran sodium
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3052628 | 2020C/532 | Belgium | See Plans and Pricing | PRODUCT NAME: GIVOSIRAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1428 20200304 |
| 3052628 | 37/2020 | Austria | See Plans and Pricing | PRODUCT NAME: GIVOSIRAN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/20/1428 (MITTEILUNG) 20200304 |
| 3052628 | C20200026 00361 | Estonia | See Plans and Pricing | PRODUCT NAME: GIVOSIRAAN;REG NO/DATE: EU/1/20/1428 04.03.2020 |
| 3052628 | 20C1040 | France | See Plans and Pricing | PRODUCT NAME: GIVOSIRAN OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; NAT. REGISTRATION NO/DATE: EU/1/20/1428 20200304; FIRST REGISTRATION: - EU/1/20/1428 20200304 |
| 3052628 | CA 2020 00042 | Denmark | See Plans and Pricing | PRODUCT NAME: GIVOSIRAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/20/1428 20200304 |
| 3052628 | 724 | Finland | See Plans and Pricing | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
